Jeffrey Dierks Sells 10,507 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jeffrey Dierks also recently made the following trade(s):

• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $39.05 on Friday. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of 18.51, a price-to-earnings-growth ratio of 0.49 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a 52 week low of $28.14 and a 52 week high of $41.61. The firm has a 50-day simple moving average of $34.39 and a 200-day simple moving average of $34.84. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. During the same period last year, the company posted $0.63 EPS. The business’s revenue was up 16.0% on a year-over-year basis. On average, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.42 earnings per share for the current fiscal year.

Institutional Trading of Harmony Biosciences

Several large investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. boosted its position in shares of Harmony Biosciences by 0.6% during the 2nd quarter. Pacer Advisors Inc. now owns 2,509,609 shares of the company’s stock valued at $75,715,000 after acquiring an additional 14,695 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Harmony Biosciences by 13.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock valued at $28,871,000 after purchasing an additional 112,197 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Harmony Biosciences by 53.7% in the 2nd quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock valued at $20,562,000 after buying an additional 238,140 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Harmony Biosciences by 27.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after buying an additional 140,690 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Harmony Biosciences by 56.7% during the 2nd quarter. Renaissance Technologies LLC now owns 595,800 shares of the company’s stock valued at $17,975,000 after buying an additional 215,700 shares during the period. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Oppenheimer restated an “outperform” rating and set a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Raymond James reissued an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a report on Thursday, October 10th. Mizuho increased their target price on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. Cantor Fitzgerald lifted their price target on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, January 13th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.